Subsidiaries & Partners

Cytocom consists of a number of subsidiary and partner companies advancing a portfolio of dedicated programs with strong clinical validation.

Genome Protection, Inc.

Genome Protection, Inc. (GPI), is a partially owned subsidiary making significant inroads in the longevity space

We are a longevity biotech company

Our founders and scientists have dedicated their lives to studying the genome and its role in aging and cancer. We believe that aging is a disease and thus can be treated. Our goal is to develop such treatments to significantly prolong healthy lifespan and protect against the many diseases of aging.

Genome protection is our primary area of expertise

The human genome entombs ancient viruses called retroelements that, when awakened, propagate and wreak havoc on our cells. We aim to develop drugs that protect against cancer and age-related diseases by neutralizing the various retroelements that we collectively call the ‘retrobiome’.

We have come a long way in our quest

Some of our therapies are already in the clinic, i.e. being tested in humans, while others are still in preclinical stages but rapidly maturing. Our partnerships with top academic institutions provide access to leading scientific and medical experts and create a powerful foundation for rapid hypothesis testing and expedited clinical translation.

Areas of Focus

Retrobiome management
Pharmacological inhibition of intrinsic DNA damage caused by retroelements with the goal of decreasing cancer adaptability, combating aging and prolonging healthy longevity.
Immunostimulation
Stimulation of specific branches of innate immunity for eradication of genome-compromised cells with the goal of extending healthy longevity.
Retrobiome vaccination
Induction of an immune response directed against cells with active retroelements with the goal of prolonging healthy longevity and reducing risks of age-related diseases.

ImQuest Life Sciences

ImQuest Life Sciences, Inc., is a contract research and development company focused specifically on cancer, inflammation and infectious disease treatments.  ImQuest Pharmaceuticals was merged into Cytocom’s existing drug development operations, and ImQuest Biosceinces, the contract research organization (CRO), operates as wholly-owned, revenue-generating subsidiary of Cytocom.

Customized Drug Discovery and Development Services

ImQuest BioSciences is a preclinical CRO that provides expert services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases. These preclinical research services are part of our ImQuestSUCCESS Platform and include compound screening to define compound efficacy and drug target validation to define the mechanism of action and toxicity of pharmaceutical products.

We specialize in services for the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines.

We are committed to earning our client’s trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in preclinical contract research. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

Areas of Focus

  • Virology
  • Microbiology
  • Oncology
  • In vitro Toxicology
  • Pharmaceutical Properties and Characterization
  • Microbicides and STI Prevention
  • Supportive Technical Services
  • Consulting Services

Panacela Labs

Panacela Labs, is a majority-owned subsidiary developing Mobilan, based on non-replicating adenovirus vector delivery system encoding TLR5 and corresponding ligand

Panacela Labs Inc. maintains a focus on oncology and orphan drug develo pment, some drugs of which are on the stage of clinical studies and is developing Mobilan, an innovative anticancer drug product in collaboration with the Roswell Park Cancer Institute (Buffalo, USA) and  Cleveland Clinic Foundation (Cleveland, USA).

Mobilan’s action includes transduction of tumor cells with bicistronic recombinant non-replicating adenovirus which manages expression of human Toll-like receptor of 5 type (TLR5) and its specific ligand-agonist, 502s, pharmacologically optimized analogue of bacterial protein flagellin. The derived constitutive autocrine stimulation of signaling pathway TLR5 results in response of innate immunity and subsequent development of adaptive anti-tumor immune reactions.

The proprietary technology allows to convert any available tumor node to the vaccine activating innate and further acquired immunity which may be used for treatment of various cancer neoplasms.

Areas of Focus

Prostate Cancer
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer

Incuron, LLC

Incuron, LLC. is a royalty partner with Cytocom focused on the development of innovative medicines for the treatment of cancer and auto-immune diseases, based on Curaxins – a novel class of chemical structures

Incuron’s clinical lead curaxin CBL0137, demonstrated significant anti-cancer activity in a number of preclinical tumor models, including colon, pancreatic, prostate and breast adenocarcinomas, melanoma, kidney cancer, glioblastoma, hematological malignancies, and several pediatric malignancies, including neuroblastoma. It showed efficacy both as a monotherapy and in combination with standard of care and various targeted therapies. In animal studies, significant inhibition of tumor growth, and in some cases complete tumor eradication, was observed at non-toxic concentrations of. CBL0137 is currently being tested in several clinical studies against solid and hematological malignancies.

Areas of Focus

Solid Tumors, IV administration, USA

Solid Tumors, Oral administration, RUS

Hematological Malignancies